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The use of defined protein and peptide antigens can overcome specificity limitations of purified protein
derivatives in the detection of bovine tuberculosis when the antigens are used in blood-based tests. Since the
use of these specific antigens as skin test reagents could have practical advantages, we investigated the
potential of Mycobacterium bovis-specific antigens to stimulate delayed-type hypersensitivity (DTH) responses
in cattle experimentally infected with M. bovis. A cocktail of the recombinant antigens ESAT-6, MPB83, and MPB64
failed to stimulate in vivo DTH in cattle that had been experimentally infected with M. bovis despite the fact that the
antigens were recognized in vitro by the same animals. However, it was possible to stimulate antigen-specific bovine
DTH responses by using ESAT-6 in combination with a synthetic bacterial lipopeptide. This lipopeptide stimulated
the release of the proinflammatory cytokine tumor necrosis factor alpha from monocyte-derived bovine dendritic
cells in vitro, thereby providing a possible mechanism for its DTH-enhancing properties.
Bovine tuberculosis (TB) is a disease of economic and zoo-
notic importance caused by the intracellular bacterium Myco-
bacterium bovis. In the United Kingdom, there has been a
steady rise in the incidence of bovine TB during the last de-
cade, and the cost of control measures currently exceeds £25
million per annum. Bovine TB is a zoonotic disease, and prior
to introduction of milk pasteurization and disease control mea-
sures in England, up to 6% of human deaths (2,500 people per
annum) resulting from TB were attributed to M. bovis infection
(19). Furthermore, the zoonotic impact of bovine TB remains
an important consideration in developing countries in which
limited or no control measures are in place (26, 27). The early
and specific diagnosis of this disease in cattle is therefore of
vital importance.
The control of bovine TB in the United Kingdom relies on
detection of infected animals by the single comparative intrader-
mal tuberculin test (SCITT) (32). This test detects the develop-
ment of a delayed-type hypersensitivity (DTH) response to intra-
dermal injection of a purified protein derivative (PPD) prepared
from an M. bovis culture. The reaction to bovine PPD (PPD-B) is
compared to the skin reaction induced by a Mycobacterium
avium-derived PPD to provide a measure of sensitization to en-
vironmental mycobacteria. Cattle presenting with a positive skin
test are slaughtered (test and slaughter control policy).
Recent advances in the detection of bovine and human TB
have demonstrated that the use of defined protein and peptide
antigens can overcome specificity limitations of PPD; for ex-
ample, this can occur in populations that have been vaccinated
with M. bovis BCG (bacillus Calmette-Gue´rin). In cattle, re-
cent studies have demonstrated that defined M. bovis antigens,
such as ESAT-6, MPB64, MPB70, and MPB83, can distinguish
BCG-vaccinated animals from M. bovis-infected animals while
still providing high levels of sensitivity for diagnosing M. bovis
infection (8, 43).
To date, in such studies and studies in which the diagnostic
applications of defined protein antigens against bovine TB
have been investigated (14, 35, 36) the workers have used in
vitro blood-based assays to assess the performance of the can-
didate antigens. Compared to the traditional skin test, blood-
based diagnostic assays have advantages that include the re-
quirement for only a single farm visit and no retest interval
restrictions, unlike the recommended 60-day retest interval
associated with the SCITT (37). However, skin testing remains
a simple, cheap, robust, and widely accepted diagnostic tool
whose application could still prove to be useful when field
applications of more specific defined diagnostic reagents are
considered.
The purpose of the present study was to investigate the
diagnostic potential of defined M. bovis antigens as skin tests
reagents in cattle. We report here that a protein cocktail com-
prising recombinant forms of the ESAT-6, MPB64, and
MPB83 antigens was found to be a potent DTH-inducing an-
tigen combination in a guinea pig model, yet it failed to induce
DTH responses in M. bovis-infected cattle despite the fact that
it was recognized in vitro in the same animals. However, the
failure of the defined mycobacterial antigens to induce bovine
DTH responses was overcome by coadministration of a syn-
thetic bacterial lipopeptide with proinflammatory properties.
MATERIALS AND METHODS
Bacterial strains. M. bovis strain AN5 was supplied by the Tuberculin Pro-
duction Unit, Veterinary Laboratories Agency (VLA), Addlestone, United King-
dom. M. bovis stain AF2122/97 was supplied by the TB Diagnostic Unit (VLA).
Both strains were stored frozen in Middlebrook 7H9 culture media (Becton
Dickinson, Oxford, United Kingdom). The number of viable CFU was deter-
mined by plating an aliquot of a strain on Middlebrook 7H10 agar (Becton
Dickinson) supplemented with 10% (vol/vol) oleic acid-albumin-dextrose-cata-
lase (Becton Dickinson). Agar plates were also supplemented with 0.2% (vol/vol)
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glycerol (Sigma, Poole, United Kingdom) for growth of AN5 and with 4.16 g of
pyruvic acid (Sigma) per liter for growth of AF2122/97.
Mycobacterial antigens. The recombinant M. bovis antigens ESAT-6, MPB70,
and MPB83 were produced as previously described (43). Recombinant MPB64
was kindly provided by D. Bakker, Animal Health Science, Boxtel, The Nether-
lands. PPD-B and avian PPD (PPD-A) were produced and supplied by the
Tuberculin Production Unit (VLA) according to procedures prescribed by the
European Pharmacopoeia (12). For assessment of the purity of antigens, samples
were separated on 8 to 18% precast gel sodium dodecyl sulfate (SDS)-polyacryl-
amide gel electrophoresis (PAGE) gels (Amersham-Pharmacia Biotech, Little
Chalfont, United Kingdom), and electrophoresis was performed by using a
Multiphor II system (Amersham-Pharmacia Biotech). Sample purity was as-
sessed by performing total-protein staining of gels with a commercial silver
staining kit (Amersham-Pharmacia Biotech) and by using a standard Western
blot procedure to probe for the presence of contaminating Escherichia coli
proteins with rabbit anti-E. coli polyclonal antibody sera (Dako Ltd., Ely, United
Kingdom).
Protease treatment of PPD-B was performed with a lyophilized aliquot of
international standard bovine tuberculin PPD (NIBSC, Potters Bar, United
Kingdom). The PPD-B standard was reconstituted at a concentration of 1 mg/ml
and then incubated (1-ml aliquot) in the presence of 5 l of a 10-mg/ml solution
of proteinase K (Sigma) for 5 min at 37°C. The sample was then incubated at
65°C for 5 min to heat inactivate the enzyme. The proteinase K treatment was
repeated two more times. The sample was then incubated in the presence of 10
l of a 10-mg/ml solution of pronase (Roche Diagnostics Ltd., Lewes, United
Kingdom) for 90 min at 25°C. Finally, the pronase was heat inactivated at 80°C
for 10 min.
Protein concentrations of noncommercially derived materials were deter-
mined with a bicinchoninic acid protein assay kit (Perbio Science UK Ltd.,
Tattenhall, United Kingdom).
Cattle and guinea pig experimental infections. Guinea pigs that weighed 350
to 400 g and were free of intercurrent infection were obtained from Charles
River UK Ltd., Margate, United Kingdom. The guinea pigs were infected with
100 CFU of M. bovis AN5 in 0.25 ml of phosphate-buffered saline (PBS) by
intramuscular injection into the flexor muscles of the crus region of the right hind
leg. The route of infection and the strain of M. bovis used were in accordance
with the recommendations of the European Pharmacopoeia for evaluation of the
potency of PPD-B (12).
Cattle that were approximately 6 months old were obtained from United
Kingdom herds free of bovine TB. Calves were infected with 5  104 CFU of M.
bovis AF2122/97 by endobronchial challenge as described previously (7). The
infection status of all animals was confirmed by the presence of tuberculous
lesions at postmortem and by culture of M. bovis from isolated tissues. A total of
16 infected calves were used in this study.
DTH skin tests. Guinea pig skin tests were performed with animals 5 weeks
following experimental infection with M. bovis AN5. Both flanks of a guinea pig
were shaved and depilated prior to intradermal injection of 0.1 ml of antigen. Up
to four sites on each side of the guinea pig were used. The extent of the
erythematous reaction was measured with calipers 24 h later and was expressed
as the mean of two measurements taken at right angles to each other delineating
the reaction area. Statistical analysis of the responses induced by each of the
protein cocktails was performed by using repeated measures of analysis variance
with Tukey-Kramer posttest analysis, while a measure of the strength of the
responses was represented by the mean  standard deviation.
Cattle skin tests were performed with infected animals 16 to 20 weeks follow-
ing experimental infection with M. bovis AF2122/97. The skin test was performed
in accordance with the standard SCITT procedure (13). Each antigen prepara-
tion (0.1 ml), supplied coded to the veterinary surgeon performing the test, was
injected intradermally into the neck of the animal. Up to four sites on each side
of the neck were used. The normal skin thickness at the injection site was
measured with calipers prior to antigen administration and then again 72 h later.
The results were expressed as the difference between the measurements obtained
at time zero and 72 h.
Bovine lymphocyte transformation assay. Peripheral blood mononuclear cells
(PBMC) were isolated from heparinized blood by gradient centrifugation on
Histopaque 1077 (Sigma) and were cultured in RPMI 1640 Glutamax-1 (Life
Technologies, Paisly, United Kingdom) supplemented with 5% complete protein
serum replacement 1 (Sigma), nonessential amino acids (Sigma), 5 M 2-mer-
captoethanol (Sigma), penicillin (100 U/ml; Life Technologies), and streptomy-
cin sulfate (100 g/ml; Life Technologies). PBMC were cultured in triplicate at
a concentration of 2  105 cells/well (volume, 0.2 ml) at 37°C with 5% CO2 for
6 days in flat-bottom 96-well culture plates in the presence of antigen, and they
were labeled during the final 18 h of culture with 37 kBq of [3H]thymidine
(Amersham-Pharmacia Biotech) per well. The cultures were harvested on glass
fiber filters and counted with a TopCount NXT beta counter (Perkin Elmer Life
Sciences, Zarentem, Belgium). Responses to defined protein antigens were con-
sidered positive when the stimulation index (SI) (counts per minute with antigen/
counts per minute without antigen) was 2 and the signal strength was 1,000
cpm. When the responses to PPD-B were compared with the responses to
PPD-A, a response was considered positive when the SI with PPD-B was greater
than that with PPD-A and the PPD-B-induced SI was 3 with a signal strength
1,000 cpm.
Bovine monocyte-derived DC culture. Bovine dendritic cells (DC) were de-
rived from CD14 monocytes that were isolated from PBMC and cultured with
granulocyte-macrophage colony-stimulating factor and interleukin-4 (IL-4) as
previously described by Hope et al. (23). After 3 days of culture, the synthetic
bacterial lipopeptide Pam3CSK4 (EMC Microcollections, Tubingen, Germany)
(42, 45), where Pam3C is a palmitoyl-Cys[(RS)-2,3-di(palmitoyloxy)-propyl] res-
idue, was added to the DC. Supernatants were harvested 48 h later and assayed
for the presence of bovine tumor necrosis factor alpha (TNF-) by using a
luminometric enzyme-linked immunosorbent assay (ELISA) protocol.
TNF- luminometric ELISA. Antibodies to TNF- were generated by immu-
nization of mice with recombinant bovine TNF- and hybridomas generated in
a manner similar to that described previously for IL-12 (22). A pair of mono-
clonal antibodies, designated CC327 and biotinylated CC328, were shown to
recognize recombinant and native bovine TNF- in ELISA (J. C. Hope, L. S.
Kwong, and C. J. Howard, unpublished data) when a protocol similar to that
developed for assaying IL-12 (22) was used. U-bottom black 96-well plates
(Porvair, Shepperton, United Kingdom) were coated with 2 g of CC327 per ml
overnight at room temperature. The plates were washed with PBS containing
0.01% Tween 20 (wash buffer) and then blocked by using sodium casein (1 mg/ml
in PBS) for 1 h at room temperature. The plates were washed, and DC culture
supernatant or a COS cell-derived TNF- standard (Institute for Animal Health)
was added to the appropriate wells. Following a 1-h incubation at room temper-
ature, the plates were washed again and then incubated in the presence of
biotinylated CC328 (1 g/ml) for an additional 1 h. The plates were washed and
then incubated in the presence of horseradish peroxidase-labeled streptavidin
(Amersham-Pharmacia Biotech) for 45 min at room temperature. Following the
final wash, the Super Signal ELISA femto maximum-sensitivity substrate (Per-
bio) was added to each well, and the number of relative light units was deter-
mined 1 min later with an Anthos LUCY 1.0 luminometer (AnthosLabtec,
Salzburg, Austria). The number of biological units of TNF- per milliliter was
calculated by comparison with the bovine standard.
RESULTS
Screening of candidate antigens in a guinea pig DTH model.
The homogeneity of recombinant antigens ESAT-6, MPB64,
MPB70, and MPB83 was confirmed prior to investigation in
animals by SDS-PAGE analysis (Fig. 1). While ESAT-6,
FIG. 1. Assessment of the purity of recombinant mycobacterial an-
tigens. The homogeneity of recombinant mycobacterial antigens was
determined by separation on an SDS-PAGE gel and staining for pro-
tein by a silver staining procedure (A) or by transferring the protein to
a nitrocellulose membrane and probing with polyclonal anti-E. coli
rabbit sera to detect contaminating E. coli proteins (B). Lanes 1 to 5
contained ESAT-6 (0.5 g), MPB64 (0.5 g), MPB70 (0.5 g), MPB83
(0.5 g), and E. coli cell sonicate (10 g), respectively.
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MPB64, and MPB70 produced single bands at the expected
molecular masses, an additional band at a molecular mass of
50 kDa was obtained for MPB83 along with the expected
product at a molecular mass of 25 kDa (Fig. 1A, lane 4).
However, this band, as well as the 25-kDa product, reacted
with an MPB83-specific monoclonal antibody (data not shown)
but not with anti-E. coli antibodies (Fig. 1B, lane 4). We there-
fore concluded that this 50-kDa product was a dimeric form of
recombinant MPB83.
The DTH-inducing potential of these antigens was first
tested in a guinea pig skin test model to help define an opti-
mized antigen combination that could be used for further in-
vestigations in cattle. Each of the antigens stimulated DTH in
a proportion of the guinea pigs tested, and ESAT-6 induced
DTH responses most frequently (Fig. 2) (for MPB64 there
were responses in three of eight animals; for MPB70 and
MPB83 there were responses in four of eight animals; and for
ESAT-6 there were responses in six of eight animals). The
combination of ESAT-6 and MPB83 stimulated DTH re-
sponses in all of the guinea pigs (12.7  0.5 mm) (Fig. 2).
However, the optimal protein cocktail contained ESAT-6,
MPB64, and MPB83 since this cocktail induced significantly
stronger DTH responses (P  0.05) than the ESAT-6–MPB83
combination (14.5  1.5 mm). Addition of MPB70 to this
cocktail resulted in no significant increase in the strength of the
responses observed (14.4  1.7 mm). In contrast to PPD-B,
which gave an increase in skin thickness of 15.6  1.3 mm,
none of these proteins induced skin test responses in BCG-
vaccinated guinea pigs when the proteins were tested individ-
ually or in combination (data not shown), thereby confirming
their high specificity.
DTH response to mycobacterial antigens in cattle. The most
promising protein combination identified in guinea pigs
(ESAT-6, MPB64, and MPB83) was then tested as a skin test
reagent in five calves experimentally infected with M. bovis.
These animals were selected because we observed in vitro
recognition of the protein cocktail by T cells isolated from each
of them, as demonstrated by the proliferative responses shown
in Fig. 3A. After injection of the skin test reagents, all cattle
exhibited a strong DTH response to PPD-B, which was at least
4 mm greater than the response induced by PPD-A, thereby
confirming the tuberculin skin test-positive status of the ani-
mals (Fig. 3B). In contrast, in comparison to the PBS control
in the same animals, the protein cocktail induced no DTH
response in three of the calves and a poor response (2 mm) in
the remaining calves (Fig. 3B).
Bacterial lipopeptide can promote antigen-specific DTH re-
sponses in cattle. We postulated that since we had determined
that antigen-specific T cells were present in the peripheral
blood of our M. bovis-infected cattle (Fig. 3A), the inability of
the protein cocktail to induce bovine DTH was likely to be due
in part to a failure to recruit effector T cells to the site of
FIG. 2. DTH responses to mycobacterial antigens in guinea pigs.
Antigen-stimulated DTH was tested in guinea pigs that had been
infected with 100 CFU of live M. bovis by the intramuscular route.
Intradermal administration of antigens either individually (2 g) or in
combination (2 g of each constituent) was performed 5 weeks postin-
fection, and the erythematous DTH reaction was read 24 h later. E6,
ESAT-6; 83, MPB83; 64, MPB64; 70, MPB70.
FIG. 3. Lymphocyte transformation assay and DTH responses to
mycobacterial antigens in cattle. Lymphocyte transformation assay
(A) and skin test (B) responses were tested in calves experimentally
infected with 5  104 CFU of M. bovis approximately 16 weeks postin-
fection. PBMC were cultured in the presence of protein cocktail (5 g
of each component protein per ml), PPD-B, or PPD-A (10 g/ml) for
6 days, and incorporation of [H3]thymidine was determined during the
final 18 h of culture. Responses to the protein cocktail were considered
positive if the SI (antigen-stimulated proliferative response/no-antigen
response) was 2 and proliferation was 1,000 cpm. Skin test re-
sponses in the same animals were determined by intradermal admin-
istration of the protein cocktail (20 g of each component antigen) or
PPD-B plus PPD-A (100 g). The increase in skin induration was
measured 72 h later.
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antigen administration due to an inability to induce proinflam-
matory cytokines. Therefore, we investigated whether poten-
tial proinflammatory stimuli were able to promote the DTH
responses induced by recombinant mycobacterial protein an-
tigens. As PPD itself has been shown to induce proinflamma-
tory cytokines during DTH responses (9), we first assessed
whether nonprotein components of PPD were able to enhance
specific DTH responses to ESAT-6, MPB64, and MPB83. We
therefore formulated these proteins together with protease-
treated PPD-B, which by itself does not stimulate DTH in M.
bovis-infected cattle or guinea pigs (data not shown), and we
tested the DTH-inducing properties of this antigen formula-
tion in three M. bovis-infected calves. However, protease-
treated PPD-B failed to promote DTH responses to the three
recombinant antigens in these calves (data not shown).
We next investigated the potential DTH-enhancing proper-
ties of a synthetic bacterial lipopeptide, Pam3CSK4. This
model lipopeptide contains acyl moieties that mimic those
identified in bacterial lipoproteins (47), and it has been shown
to be capable of inducing TNF- from murine and human
monocytes (4, 21), a proinflammatory cytokine important in
the in vivo recruitment of T cells (25). This lipopeptide was
tested in combination with ESAT-6, the immunodominant an-
tigen of the protein cocktail, in seven calves experimentally
infected with M. bovis. Each of these calves exhibited positive
recognition of ESAT-6 in vitro, as determined by the T-cell
proliferation assay (median SI, 5.9; SI range, 2.0 to 50.6). As
expected, ESAT-6 alone failed to induce a DTH response in
any of these calves. However, when ESAT-6 was coadminis-
tered with the lipopeptide, DTH responses were induced in
four of the animals (Fig. 4A). The modulation of ESAT-6-
induced DTH responses by the lipopeptide in these infected
calves was demonstrated to be antigen specific since the li-
popeptide control in these calves induced no measurable re-
sponse (Fig. 4A) and, furthermore, when ESAT-6 and the
lipopeptide were administered alone or in combination, they
stimulated no measurable DTH response in four SCITT-neg-
ative uninfected calves (reaction sizes, 0 mm).
To investigate a molecular mechanism by which the syn-
thetic lipopeptide could stimulate enhanced inflammatory re-
sponses, we quantified the presence of the proinflammatory
cytokine TNF- in culture supernatants of monocyte-derived
bovine DC stimulated with Pam3CSK4. As shown in Fig. 4B,
Pam3CSK4 was able to induce bovine DC to produce TNF- in
a dose-dependent manner.
DISCUSSION
Defined antigens of M. bovis have demonstrated much
promise in overcoming specificity limitations of PPD for diag-
nosing bovine TB when they are used in blood-based in vitro
assay formats (8, 14, 35, 36, 43). However, investigation of such
antigens as bovine skin test reagents has not been reported
previously and therefore was the subject of the present study.
ESAT-6, MPB64, and MPB70 have previously been shown to
be capable of stimulating DTH responses in guinea pigs that
were infected or sensitized with either live Mycobacterium tu-
berculosis, M. bovis BCG, or heat-killed M. bovis strains (1, 11,
15, 18, 31, 34). The demonstration that recombinant forms of
these antigens also induced DTH in M. bovis-infected guinea
pigs in the present study confirmed that DTH-inducing anti-
gens may be useful as skin test reagents in cattle. In addition,
we also identified MPB83 as another promising DTH-inducing
antigen whose potential for diagnosing bovine TB through
detection of cellular immune responses has been demonstrated
previously only in vitro (14, 43).
Having defined an antigen cocktail that induced DTH re-
sponses in guinea pigs that were comparable to those induced
FIG. 4. Synthetic bacterial lipopeptide promotes enhanced bovine
DTH and stimulates TNF- production from bovine DC. (A) Skin test
responses to the lipopeptide Pam3CSK4 and ESAT-6 were tested in
cattle that had been infected with 5  104 CFU of live M. bovis.
Intradermal administration of ESAT-6 (100 g) either alone or in the
presence of synthetic lipopeptide (20 g) was performed 16 weeks
postinfection, and the increase in skin induration was read 72 h later
(all cattle exhibited strong PPD-B responses). (B) TNF--inducing
properties of Pam3CSK4 were tested by using bovine monocyte-de-
rived DC. Bovine CD14 monocytes were cultured in the presence of
granulocyte-macrophage colony-stimulating factor and IL-4 for 3 days
and then for an additional 2 days in the presence of Pam3CSK4. The
TNF- in culture supernatants was determined by using a luminomet-
ric ELISA and was quantified by comparison with a bovine TNF-
standard. The data are representative of the results of one of three
independent experiments.
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by PPD-B, we tested the ability of this cocktail to detect M.
bovis infection in the target host. However, this cocktail failed
to stimulate measurable DTH in infected calves. These calves
were not deficient in the ability to mount DTH responses since
PPD-B induced strong skin responses in each of them. This
observation is analogous to the results of a clinical study in
which the workers investigated MPT64 as a skin test reagent in
TB patients. Like the proteins tested in the present study,
MPT64 was selected for a clinical investigation due to its ability
to induce specific and potent DTH responses in M. tuberculo-
sis-infected guinea pigs (18, 20). However, it also failed to
induce DTH in the majority of the patients tested (46). We
considered that the explanation for the exquisite sensitivity of
guinea pigs to induce DTH compared with the sensitivities of
other hosts may be related to differences in the cellular com-
positions of the dermis and epidermis. The cells present in the
skin that have an important role in mediating DTH include
mast cells, which increase vascular permeability through the
release of vasoactive amines (2, 16), and Langerhans cells,
which are potent antigen-presenting cells of the DC lineage
(39). However, a review of literature indicated that the densi-
ties of Langerhans cells in the epidermis of guinea pigs and in
the epidermis of cattle are equivalent (6, 38), while the densi-
ties of mast cells in cattle dermis and human dermis are actu-
ally greater than the density observed in guinea pigs (17, 28).
Therefore, while the differences in sensitivity between guinea
pig and cattle (and human) DTH remain unclear, these data
suggest that caution should be used when attempting to ex-
trapolate quantitative DTH data between these species.
The calves used in the present study were considered suit-
able for investigating the DTH-inducing properties of the de-
fined protein cocktail since we were able to demonstrate that in
each animal, T cells present in PBMC recognized the cocktail
in vitro. However, while in vitro assays demonstrate that anti-
gen-specific T cells have been generated, such assays do not
model the inflammatory process that is required to recruit
antigen-experienced T cells to sites of local antigen exposure in
vivo. It has long been recognized that injection of protein
antigens in the absence of a suitable adjuvant results in poor
humoral and cell-mediated immune responses. In a recent
review of the in vivo recruitment of CD4 T cells (24), the
workers proposed that the role of the adjuvant is to stimulate
the release of proinflammatory cytokines, such as TNF- and
IL-1, which promote migration of DC both to the site of an-
tigen administration and subsequently to the draining lymph
nodes after digestion of the antigen. The presentation and
recognition of the antigen by memory T cells in turn lead to an
influx of monocytes, macrophages, and T cells to the site of
antigen administration. In the absence of an adjuvant stimulus,
presentation of the antigen should be insufficient due to the
low level of DC migration that occurs under noninflammatory
conditions (24). Therefore, we concluded that the poor per-
formance of the protein cocktail as a skin test reagent in our
cattle was probably due in part to the absence of a suitable
proinflammatory stimulus.
PPD is itself a potent DTH-inducing antigen that, due to its
crude method of manufacture, can contain up to 15% nonpro-
tein components, including DNA and cell wall-derived lipids
and carbohydrates (30). Since mycobacterial cell wall compo-
nents and DNA are both known to be potent adjuvants for
cell-mediated responses (3, 40), we speculated that the non-
protein constituents of PPD might provide an important com-
ponent of the proinflammatory signal required to promote the
antigen-specific component of DTH responses. However,
PPD-B depleted only of its protein component by treatment
with proteases failed to promote bovine DTH responses to the
protein cocktail.
Bacterial lipoproteins and lipopeptides from a diverse range
of bacteria, including E. coli, Borrelia burgdorferi, Treponema
pallidum, Mycoplasma fermentans, and M. tuberculosis, have
been shown to induce proinflammatory cytokine production
from monocytes and macrophages through triggering of the
innate pattern recognition signal Toll-like receptor 2 (5, 29).
Similarly, a synthetic lipopeptide containing an acyl moiety
that models that of bacterial lipoproteins (47) has also been
shown to stimulate the production of proinflammatory cyto-
kines, including TNF- (4, 21, 33). Therefore, we investigated
this synthetic bacterial lipopeptide, Pam3CSK4, in combination
with ESAT-6 and demonstrated that it was capable of promot-
ing antigen-specific DTH responses in more than one-half of
the calves tested. The immunomodulatory influence of this
lipopeptide was not observed in vitro since Pam3CSK4 did not
enhance ESAT-6-stimulated T-cell proliferation when the two
reagents were cocultured in the presence of PBMC (data not
shown), although this result may reflect the in vitro culture
conditions used rather than indicate a complete inability of the
lipopeptide to enhance T-cell responses in vitro. Since we were
then able to demonstrate that Pam3CSK4 stimulated the pro-
duction of TNF- from monocyte-derived DC, we propose
that the molecular mechanism for the DTH-enhancing prop-
erties of this compound involves an ability to induce TNF-
and other proinflammatory cytokines in vivo, thereby promot-
ing enhanced migration of DC and infiltration of monocytes,
macrophages, and T cells. However, to be able to consider
formulations based on defined antigens as skin test reagents in
cattle for general field applications, further optimization is
required. In addition, it is necessary to ensure that the diag-
nostic sensitivity of such a skin test is at least as good as that of
an equivalent blood-based assay by, for example, inclusion of
additional antigens, such as CFP-10, which have been shown to
be useful in diagnosing bovine TB (10, 41, 44).
In summary, our data indicate that the development of a
skin test for bovine TB in which defined antigens are used
presents many more challenges than the development of
blood-based tests. However, we demonstrated that the limita-
tions of defined mycobacterial antigens to induce DTH re-
sponses in cattle may be overcome by using them in combina-
tion with a suitable proinflammatory stimulus, although further
test optimization, such as optimization of antigen concentra-
tions or the time that the reactions are read, is necessary if
practical application of defined antigens as skin test reagents
for bovine TB is to be realized.
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